Search Results

Fennec Pharmaceuticals Inc. and Norgine announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand.

Norgine is pleased to announce the appointment of Saulo Martiniano as its new Chief Operating Officer.

NORGINE B.V. a leading European specialist pharmaceutical company and US WorldMeds, a Kentucky-based specialty pharmaceutical company, announced an exclusive licensing agreement by which Norgine will register and commercialise difluoromethylornithine, DFMO in Europe, Commonwealth of Independent States, Australia and New Zealand.

Olympus Corporation announced it has signed a definitive agreement to acquire Arc Medical Design Limited, a subsidiary of Norgine B.V.

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, is pleased to note the announcement today by Norgine that they have launchedFeraccru® in the UK.

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, reported its financial results for the first quarter ended March 31, 2024, and provided a business update.